Our results proved that SA ameliorates NAFLD via modulating gut microbiota and its metabolites to suppress the TLR4/NF-κB/NLRP3 inflammatory pathway in the livers of rats (Figure 7). This evidence concerns the gene NFKB1 and metabolic dysfunction-associated steatotic liver disease.